PROKProKidney Corp. Class A Ordinary Shares

CSNasdaq (XNAS)·USD

Identity

Security key: 20362
Ticker: PROK
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2022-07-12
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: PROK

Detail

Enriched 2026-08-14 20:47

Market cap: $303,695,575.24
Shares outstanding (class): 205,199,713
Shares outstanding (weighted): 205,199,713
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 231
Location: WINSTON-SALEM, NC
Homepage: https://www.prokidney.com
Description: ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Market cap and share counts drift.

Funds holding this security

12 funds · 12 positions · $8.79M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$2.05M	0.00%	1,146,937 NS	FIGI
Morgan Stanley Insight Fund Morgan Stanley Insight Fund	—	$2.00M	0.18%	1,119,402 NS	FIGI
Morgan Stanley Discovery Portfolio Brighthouse Funds Trust I	—	$1.94M	0.17%	1,082,616 NS	FIGI
Discovery Portfolio MORGAN STANLEY INSTITUTIONAL FUND TRUST	—	$1.47M	0.20%	820,877 NS	FIGI
Inception Portfolio MORGAN STANLEY INSTITUTIONAL FUND INC	—	$523.5K	0.22%	292,440 NS	FIGI
EQ/Morgan Stanley Small Cap Growth Portfolio EQ Advisors Trust	—	$366.8K	0.09%	204,920 NS	FIGI
Discovery Portfolio MORGAN STANLEY VARIABLE INSURANCE FUND INC.	—	$305.9K	0.18%	170,911 NS	FIGI
Global Insight Portfolio MORGAN STANLEY INSTITUTIONAL FUND INC	—	$99.7K	0.19%	55,698 NS	FIGI
Goldman Sachs Absolute Return Tracker Fund GOLDMAN SACHS TRUST	—	$13.3K	0.00%	7,442 NS	FIGI
Small Cap Core Fund Northern Funds	—	$10.1K	0.00%	5,668 NS	FIGI
Total Stock Market Index Trust John Hancock Variable Insurance Trust	—	$4.2K	0.00%	2,354 NS	FIGI
State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST	—	$2.2K	0.00%	1,229 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERPROK
FIGI_COMPOSITEBBG0119BQ2Y2
FIGI_SHARE_CLASSBBG0119BQ3S7
CIK0001850270
ISINUS74291D1046
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: ProKidney is a clinical-stage biotech developing cell therapy for kidney disease, matching the biological products SIC code.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.